Follow us for updates
© 2022
Read the Story →

Moderna Says COVID Vaccine 93% Effective 4-6 Months After Jab

Efficacy is stable, company says.
by Reuters
Aug 5, 2021
Photo/s: Shutterstock

Moderna Inc said on Thursday its COVID-19 shot was about 93% effective four to six months after the second dose, showing hardly any change from the 94% efficacy reported in its original clinical trial.

That compares favorably to data released by rivals Pfizer Inc and BioNTech SE last week in which they suggested their vaccine's efficacy waned around 6% every two months, declining to around 84% six months after the second shot. Both the Moderna and Pfizer-BioNTech vaccines are based on messenger RNA (mRNA) technology.

"We are very pleased that our COVID-19 vaccine efficacy is stable at 93% from four to six months," Moderna Chief Executive Stéphane Bancel said in a statement.

"This strong duration will benefit the hundreds of millions of people who have been dosed to date with Moderna vaccines."


Moderna posted second-quarter sales of $4.4 billion, slightly above an average estimate of $4.2 billion drawn from 10 analysts polled by Refinitiv. Its COVID-19 shot is the firm's first authorized product and sales were just $67 million in the same period last year.

Continue reading below ↓

The company logged $2.78 billion in net income in the quarter or $6.46 a share, beating expectations of $2.46 billion or $5.96 a share.

A durable vaccine could mean recipients may be able to wait longer between shots if they do eventually need a booster or may even not need additional doses to prevent COVID-19.

Public health authorities around the world grappling with the highly transmissible Delta variant are debating whether additional doses of COVID-19 vaccines are safe, effective, and necessary.

Pfizer plans to ask for authorization for a third shot of its vaccine later this month, and some countries - like Israel – have already begun or plan to soon begin administering shots to older or otherwise vulnerable people.

Moderna said its ongoing studies of three different booster candidates induced robust antibody responses against important variants of concern. These included the Gamma, Beta, and Delta variants which were first identified in Brazil, South Africa, and India respectively. It said neutralizing antibody levels following the boost approached those observed after the second shot of its vaccine.

Continue reading below ↓
Recommended Videos

For this year, Moderna has signed $20 billion worth of sales and expects to be able to produce between 800 million and 1 billion doses of the vaccine. It has agreements for $12 billion in 2022, with options for another roughly $8 billion. It expects to be able to produce between 2 and 3 billion doses next year.

The company has not been able to keep pace with the production of much larger rival Pfizer, which expects to produce as many as 3 billion vaccine doses this year, and expects 2021 sales of the vaccine.

Moderna's vaccine was authorized for emergency use in adults in the United States in December and has since been cleared for emergency or conditional use in adults in more than 50 countries.

The company started the process of filing for full approval with the U.S. Food and Drug Administration in June and expects to finish its submission in August. 

Continue reading below ↓


Reportr is now on Quento. Download the app or visit the Quento website for more articles and videos from Reportr and your favorite websites.

Latest Headlines
Read Next
Recent News
Some relief from rising prices.
With the reopening of several local destinations, this app has never been more timely.
Landmark Roe vs Wade ruling of 1973 is overturned.
Its rise mirrors the rise of technology for the masses.
It cites global uncertainties for its move.
The news. So what? Subscribe to the newsletter that explains what the news means for you.
The email address you entered is invalid.
Thank you for signing up to On Three, reportr's weekly newsletter delivered to your mailbox three times a week. Only the latest, most useful and most insightful reads.
By signing up to newsletter, you agree to our Terms of Service and Privacy Policy.